TY - JOUR
T1 - 2017 international meeting of the Global Virus Network
AU - Catton, Mike
AU - Gray, Glenda
AU - Griffin, Diane
AU - Hasegawa, Hideki
AU - Kent, Stephen J.
AU - Mackenzie, Jason
AU - McSweegan, Edward
AU - Mercer, Natalia
AU - Wang, Linfa
N1 - Funding Information:
While there are new changes to the GVN headquarters staff, several other activities have continued, including the collection of acute and convalescent sera from confirmed Zika patients to aid in developing new diagnostics. The serum bank is funded by a grant from the Allergan Foundation, and samples are stored at the University of Texas Medical Branch in Galveston, Texas. In addition, Shyamasundran Kottilil and colleagues at the Institute of Human Virology in Baltimore have continued a project with the GVN to expand a training model for health care providers using DAA treatment for hepatitis C patients in India ( Mathur et al., 2017 ). The training program is funded by the Gilead Foundation. Similarly, a pilot study to develop an integrated clinical database to support community-based care of hepatitis B patients in Arunachal Pradesh, India also is under way, and is funded by the John C. Martin Foundation.
Funding Information:
GVN staff will continue to solicit patient serum samples for the Zika serum bank in Galveston, Texas. Additionally, a project to sequence and conduct phylogenetic analyses of collected Zika virus isolates is continuing in cooperation with the World Reference Centre for Emerging Viruses and Arboviruses (WRCEVA), which is funded by the National Institute of Allergy and Infectious Diseases (USA).
Publisher Copyright:
© 2018 Elsevier B.V.
PY - 2018/5
Y1 - 2018/5
N2 - The Global Virus Network (GVN) was established in 2011 to strengthen research and responses to emerging viral causes of human disease and to prepare against new viral pandemics. There are now 40 GVN Centers of Excellence and 6 Affiliate laboratories in 24 countries. The 2017 meeting was held from September 25–27 in Melbourne, Australia, and was hosted by the Peter Doherty Institute for Infection and Immunity and the Institut Pasteur. This report highlights the recent accomplishments of GVN researchers in several important areas of medical virology, including the recent Zika epidemic, infections by human papillomavirus, influenza, HIV, hepatitis C, HTLV-1, and chikungunya viruses, and new and emerging viruses in the Australasia region. Plans for the 2018 meeting also are noted.
AB - The Global Virus Network (GVN) was established in 2011 to strengthen research and responses to emerging viral causes of human disease and to prepare against new viral pandemics. There are now 40 GVN Centers of Excellence and 6 Affiliate laboratories in 24 countries. The 2017 meeting was held from September 25–27 in Melbourne, Australia, and was hosted by the Peter Doherty Institute for Infection and Immunity and the Institut Pasteur. This report highlights the recent accomplishments of GVN researchers in several important areas of medical virology, including the recent Zika epidemic, infections by human papillomavirus, influenza, HIV, hepatitis C, HTLV-1, and chikungunya viruses, and new and emerging viruses in the Australasia region. Plans for the 2018 meeting also are noted.
KW - Emerging viruses
KW - Global virus network
KW - International collaborations
KW - Medical virology
UR - http://www.scopus.com/inward/record.url?scp=85044022472&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85044022472&partnerID=8YFLogxK
U2 - 10.1016/j.antiviral.2018.02.001
DO - 10.1016/j.antiviral.2018.02.001
M3 - Review article
C2 - 29421321
AN - SCOPUS:85044022472
SN - 0166-3542
VL - 153
SP - 60
EP - 69
JO - Antiviral Research
JF - Antiviral Research
ER -